公司概述
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology enterprise dedicated to the discovery and development of novel therapeutics designed to treat fibrotic and inflammatory diseases. The company functions within the broader healthcare sector, specifically navigating the high-risk, high-reward landscape of the biotechnology industry where product pipelines are critical to long-term value creation. As of the latest reporting period, the company maintains a market capitalization of $12.02M, while specific annual revenue and employee count data are not publicly disclosed in the current dataset. This market capitalization suggests the company is in an early-stage development phase, typical for clinical-stage biotechs that prioritize R&D expenditures over immediate revenue generation, thereby positioning its valuation heavily on future potential rather than current earnings power.
财务健康
The company reports a net income of $-8,995,000 and an EBITDA of $-9,497,000, while specific revenue figures are unavailable in the current data; however, the significant gap between reported net income and EBITDA indicates substantial non-operating expenses or interest costs that impact the bottom line. Free cash flow stands at $-8,199,375, which reflects a capital-intensive operational model where cash outflows for research and development or general corporate expenses exceed operating cash generation. All three reported margins—gross margin, operating margin, and profit margin—are listed at 0.0%, a metric common in pre-revenue or low-revenue biotech stages where fixed R&D costs consume nearly all operating expenses before any profit can be realized. The balance sheet demonstrates a conservative capital structure with $10.37M in cash on hand contrasted against $0 in total debt, eliminating leverage risk and providing ample liquidity to fund ongoing clinical trials. This robust liquidity position is further evidenced by a current ratio of 9.08, indicating that the company holds nearly ten times the liquid assets required to cover its short-term obligations without needing external financing. Return on Equity is recorded at -69.5% and Return on Assets at -38.9%, metrics that reveal management is currently deploying capital to generate losses in pursuit of future product approvals rather than delivering immediate shareholder returns.
估值评估
Valuation multiples for the company include a trailing P/E ratio that is not applicable due to negative earnings, while the forward P/E is reported as -55.67, highlighting that traditional earnings-based valuation methods are currently inapplicable. The price-to-book ratio is 0.97, suggesting the market values the company's equity at slightly less than its book value, which often occurs in early-stage biotechs where tangible assets may not yet reflect the potential value of the intellectual property pipeline. Since revenue data is unavailable, the price-to-sales ratio is not applicable, and the EV/EBITDA stands at -100.09, further confirming that earnings-based valuation metrics are distorted by significant operating losses. The stock has exhibited volatility with a 52-week high of $5.88 and a 52-week low of $1.35, indicating a trading range of over 300%, though the specific current price relative to this range is not provided in the source data. With a beta of 0.58, the company's stock price demonstrates lower volatility relative to the broader market, moving at roughly 42% of the market's average sensitivity, which may appeal to investors seeking lower beta exposure within the biotechnology sector.
Growth & Income
Specific revenue growth year-over-year and earnings growth year-over-year rates are not available in the current dataset, preventing a direct comparison of earnings growth velocity against revenue expansion. The company does not pay dividends, as indicated by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm retains all available cash to reinvest into its clinical-stage pipeline and research activities rather than distributing income to shareholders. This reinvestment strategy is characteristic of clinical-stage biotechnology companies that must exhaust cash reserves to advance lead product candidates like nebokitug through clinical trials before generating commercial revenue. Consequently, the overall growth and income profile is defined entirely by capital preservation and pipeline progression, with no current income generation or dividend distribution to support investor yield requirements.